Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KL271
- Development stage
- Preclinical
- Lead developer
- Kolab
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
KL271 is a probiotic strain of Limosilactobacillus fermentum being developed by Kolab for aging-related oxidative stress. The candidate is in preclinical development and appears intended for oral administration, supported by reported survival at pH 2.0 consistent with gastric acid resistance. Preclinical data indicate antioxidant and anti-inflammatory activity, with reported effects on oxidative stress-related pathways and markers including glutamate-cysteine ligase, glutathione peroxidase, catalase, and superoxide dismutase; it has also been described as improving cognitive impairment and memory loss in experimental settings through antioxidant and anti-inflammatory mechanisms. KL271 is part of Kolab's proprietary probiotic pipeline rather than a conventional small-molecule pharmaceutical program.
- Other names
- Limosilactobacillus fermentum KL271
02
Targets
Beyond the preview
Go deeper on KL271.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KL271.